Complement and microglia mediate early synapse loss in Alzheimer mouse models
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; 21 of the 28 sources its claims cite were checked for support.
Abstract
Too much cleaning up: The complement system and microglia seek out and destroy unwanted cellular debris for the peripheral immune system as well as excess synapses in the developing brain. Hong et al. now show how the system may go haywire in adults early in the progression toward Alzheimer's disease (AD). Aberrant synapse loss is an early feature of Alzheimer's and correlates with cognitive decline. In mice susceptible to AD, complement was associated with synapses, and microglial function was required for synapse loss. The authors speculate that aberrant activation of this “trash disposal” system underlies AD pathology. Science , this issue p. 712
Overview
CoChat Summary
TL;DR
In Alzheimer mouse models, classical complement proteins C1q and C3 increase and localize to synapses before plaques, and blocking C1q, C3, or microglial CR3 reduces early synapse loss. Soluble Aβ oligomers drive microglial engulfment of synaptic material through a CR3-dependent pathway, suggesting reactivation of developmental synaptic pruning in early AD.
Key findings
- J20 hAPP mice showed significant hippocampal synapse loss at 3–4 months, before plaque deposition; loss occurred in CA1, CA3, and dentate gyrus at 3 months but not in striatum, and was not seen at 1 month.
- C1q was elevated in J20 brains as early as 1 month, region-specifically in hippocampus and frontal cortex, and colocalized with PSD95-positive puncta; Compound E reduced soluble Aβ and C1q deposition, while oligomeric Aβ—but not monomeric Aβ or vehicle—induced C1q deposition and synaptic colocalization.
- Oligomeric Aβ induced synapse loss within 72 h in WT mice but not in C1qa knockout mice; anti-C1q antibody ANX-M1 prevented oAβ-induced synapse loss and LTP impairment, and APP/PS1xC3 KO mice did not show the synapse loss seen in 4-month APP/PS1 hippocampus.
- Microglial CD68 increased in J20 hippocampus and after oAβ; oAβ increased internalized Homer-GFP in microglia, failed to do so in CR3 KO mice, and induced hippocampal synapse loss in WT but not CR3 KO mice.
Methods
- Mouse models included J20 hAPP, APP/PS1, C1qa KO, C3 KO, CR3 KO, and Homer-GFP mice, with WT littermates and ages including 1 month, 3–4 months, and P21.
- Synapse quantification used super-resolution structured illumination microscopy, confocal imaging, and electron microscopy with colocalized pre- and postsynaptic puncta markers including synaptophysin/PSD95, synaptotagmin/homer, and synapsin/PSD95; C1q and C3 colocalization with PSD95 was also measured.
- Interventions included Compound E, intracerebroventricular or tail vein injections of soluble Aβ oligomers, monomers, or vehicle, anti-C1q antibody ANX-M1 or IgG control, acute hippocampal slice LTP recordings, and an in vivo synaptic engulfment assay.
Limitations
- The paper states that specific synaptic C1q receptors are not yet known and that oAβ and C1q may act indirectly through cytokines such as TGFβ, microglial or astrocytic activation, or other pathways including MHCI/PirB.
- The paper states that the complement pathway may not be involved in all pathological routes to AD, including plaque-associated synapse loss, and that future studies are needed to examine plaque-associated synapse loss and other synaptopathies such as tauopathies and Huntington’s disease.
- Evident from the text: the findings are from mouse models and acute hippocampal slices, not human AD tissue or clinical trials, and the study focuses on early pre-plaque mechanisms rather than established plaque-associated neuropathology.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 0 Not valid · 2 Not checked · 48 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“C1q binds synapses in vulnerable regions undergoing synapse loss (our data here; (5, 27)).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [5] Stevens B The classical complement cascade mediates CNS synapse elimination. Cell 2007 131 1164 1178 18083105 source
The Results report C1q localized to synapses in the developing dLGN during synaptic pruning and relocalized to adult retinal synapses in early glaucoma, before significant synapse loss. The Discussion likewise places synaptic C1q relocalization before or concurrent with synapse loss in the glaucoma model. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [27] Stephan AH Barres BA Stevens B The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci 2012 35 369 389 22715882 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that the engulfed synapses are internalized into lysosomal compartments in a manner similar to developmental synaptic pruning (6).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [6] Schafer DP Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. Neuron 2012 74 691 705 22632727 PMC3528177 source
The Results section, “Microglia engulf RGC inputs during a period of active synaptic pruning” (page unavailable), reports that most engulfed RGC inputs colocalized with microglial lysosomal compartments. The Results section, “Microglia engulf presynaptic elements specific to RGCs” (page unavailable), also identifies an RGC presynaptic marker within microglial lysosomes, supporting the proposed similarity to developmental synaptic pruning. (LLM, conf=0.94)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Quantification of colocalized pre- and postsynaptic puncta (synaptophysin and PSD95 (Fig. 1A); synaptotagmin and homer (figs. S1A-D)) revealed a significant loss of synapses in J20 hippocampus at 3-4 months old (mo), an age that precedes plaque deposition (11, 12).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [11] Mucke L High-Level Neuronal Expression of Abeta 1-42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation. Journal of Neuroscience 2000 20 4050 10818140 PMC6772621 source
The citation is attached to the statement that 3–4 months precedes plaque deposition, not to the citing authors’ synapse measurements. In “Effects of hAPP mutations on formation of amyloid plaques” (Fig. 4; page not provided), the paper assesses mice at 2–4 months and reports amyloid deposition in APP Sw,Ind mice at 5–7 months; the paper identifies J20 as an APP Sw,Ind line. (LLM, conf=0.91)
- Supportedcites [12] Hong S Dynamic Analysis of Amyloid -Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal A during Age-Related Plaque Formation. Journal of Neuroscience 2011 31 15861 15869 22049429 PMC3227224 source
The citation follows the statement that 3–4 months precedes plaque deposition, rather than the citing authors’ own synapse measurements. The Results section (page unavailable) identifies approximately 3-month-old J20 mice as pre-plaque and describes 3–7-month-old mice as plaque-free. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Genome-wide association studies (GWAS) implicate microglia and complement-related pathways in AD (1).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [1] Hong S Dissing-Olesen L Stevens B New insights on the role of microglia in synaptic pruning in health and disease. Curr Opin Neurobiol 2016 doi:10.1016/j.conb.2015.12.004 PMC5479435 26745839 source
The Introduction says GWAS and integrated network studies identify immune-related AD risk pathways implicating microglia. The section on microglia–synapse dysfunction identifies GWAS variants CLU and CR1, both related to complement. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“C1q was also similarly increased in hippocampus of another model of AD, the APP/PS1 mice (15) (Fig. S2C).”
§ Complement and Microglia Mediate Early Synapse Loss in Alzheimer Mouse Models > Abstract
What the sources say
- Supportedcites [15] Jankowsky JL Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet 2004 13 159 170 14645205 source
The citation identifies the APP/PS1 mouse model, while the citing document points to its own Fig. S2C for the C1q increase. Figure 2 (p. 4) describes APPswe/PS1 double-transgenic mice and shows hippocampal amyloid pathology in that model. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
48 more claims · 5 with their cited sources checked
Create a free account to see all 66 claims and every source verdict.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“increasing evidence demonstrate that immune signaling may not just be a consequence of protein aggregation in the brain, but that it actually causes the buildup of aggregates at the earliest stages of the disease process.15–17”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [15]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In neurodegeneration, the complement pathway is activated, and inhibiting the complement proteins C1q or C3 results in less neuroinflammation, Aβ plaques and synapse loss29,30.”
From Exercise plasma boosts memory and dampens brain inflammation via clusterin (2021) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Before the onset of Aβ deposition, microglia engulf synapses opsonized with the complement factors C1q and C3 upon CR3-mediated recognition of C3 (121).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lack of C1q, C3, or CR3 curbed microglia activation and synaptic loss during amyloid plaque deposition.”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [139]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inappropriate control of the classical complement cascade causes unresolvable inflammation and disease (Hong et al. , 2016; Hansen, Hanson and Sheng, 2018; Morgan, 2018).”
From Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer’s Disease (2020) · cites this paper as Hong et al., 2016
Experimental — accuracy not yet measured
70 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“It is also plausible that oAβ and C1q may work indirectly to mediate synapse loss through cytokines such as TGFβ (7), through microglial or astrocytic activation, or through other mechanisms including MHCI/PirB, another immune pathway critical for synapse elimination in development and AD (28-30).”
Cited work 10.1038/nn.3560 · retracted 2022-01-13 · notice 10.1038/s41593-021-00877-7 · this paper published 2016-05-06
Citations
Cites
1 retracted
Bialas, A. R., & Stevens, B. (2013) · Nature Neuroscience · doi:10.1038/nn.3560 · Cited by 519 · cited 2×
“It is also plausible that oAβ and C1q may work indirectly to mediate synapse loss through cytokines such as TGFβ (7), through microglial or astrocytic activation, or through other mechanisms including MHCI/PirB, another immune pathway critical for synapse elimination in development and AD (28-30).”
Self-citationRetractedAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“Synaptic deficits occur in early AD and mild cognitively impaired patients before onset of plaques and are some of the first signs of the neuronal degenerative process (4, 23-25).”
Self-citationTerry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397 · cited 1×
“The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles and neuronal loss (8, 9).”
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089
Self-citationThe Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313 · cited 4×
“Although specific receptors for C1q at synapses are not yet known, C1q binds synapses in vulnerable regions undergoing synapse loss (our data here; (5, 27)).”
InfluentialSelf-citationIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“S11), indicating they are resident cells (22).”
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · cited 1×
“The degree of region-specific synapse loss is a stronger correlate of cognitive decline in AD than counts of plaques, tangles and neuronal loss (8, 9).”
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 3×
“S4), long before Aβ plaques deposit (11, 12), raising the question of whether C1q increase in these pre-plaque brains is dependent on soluble Aβ levels.”
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Cited by
Items 1,301–1,400 of 3,349
Innate immune activation: Parallels in alcohol use disorder and Alzheimer’s disease
Ramos, A., Joshi, R., & Szabó, G. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.910298 · Cited by 31
Vascular and Nonvascular Mechanisms of Cognitive Impairment and Dementia
Kara, B., Gordon, M. N., Gifani, M., Dorrance, A. M., & Counts, S. (2022) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2022.07.006 · Cited by 33
Mou, W., Ma, L., Zhu, A., Cui, H., & Huang, Y. (2022) · Molecular Pain · doi:10.1177/17448069221140532 · Cited by 36
Boeddrich, A., Haenig, C., Neuendorf, N., Blanc, E., Ivanov, A., Kirchner, M., Schleumann, P., Bayraktaroğlu, I., Richter, M., Molenda, C., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01206-2 · Cited by 39
“42 A pathology in patient brains and was previously shown to mediate synapse loss in 1013 transgenic AD models [56].”
BackgroundZou, D., Huang, X., Lan, Y., Pan, M., Xie, J., Huang, Q., Zeng, J., Zou, C., Pei, Z., Zou, C., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107098 · Cited by 31
Beggiato, S., Borelli, A. C., Ferraro, L., Tanganelli, S., Antonelli, T., & Tomasini, M. C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170699 · Cited by 29
Merlo, S., Spampinato, S. F., Beneventano, M., & Sortino, M. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-25453-1 · Cited by 30
“Aβ(1-42) peptide from Innovagen (Lund, Sweden) was dissolved in dimethylsulfoxide (DMSO) as a 5 mM stock, subsequently diluted to 100 μM in culture medium and enriched in oligomers by aggregation at RT for 24 h followed by at least 2 freeze-thaw cycles prior to use.”
The Microglial Response to Neurodegenerative Disease
Song, W. M., & Colonna, M. (2018) · Advances in immunology · doi:10.1016/bs.ai.2018.04.002 · Cited by 30
Neurodegenerative phagocytes mediate synaptic stripping in Neuro-HIV
Liberto, G. D., Égervári, K., Kreutzfeldt, M., Schürch, C. M., Hewer, E., Wagner, I., Pasquier, R. D., & Merkler, D. (2022) · Brain · doi:10.1093/brain/awac102 · Cited by 28
“able synapses by phagocytosis, leading to persistent memory impairment or other cognitive deficits.(22,24,26) However, a specific role forDAMphagocytes in theprocessof synapseeliminationandneuronal damage in Neuro-HIV has not yet been described.”
BackgroundKarczewski, J., Zielińska, A., Staszewski, R., Eder, P., Dobrowolska, A., & Souto, E. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116145 · Cited by 26
“In addition, the complement system can be activated, promoting the phagocytic function of microglia, which might result in altered pruning of synapses [78].”
BackgroundChernyaeva, L., Ratti, G., Teirilä, L., Fudo, S., Rankka, U., Pelkonen, A., Korhonen, P., Leskinen, K., Keskitalo, S., Salokas, K., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256467 · Cited by 34
Parekh, S., & Kaur, T. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1308823 · Cited by 34
Jiang, Y., Neal, J., Sompol, P. M., Yener, G., Arakaki, X., Norris, C. M., Farina, F. R., Ibáñez, A. M., Lopez, S., Al‐Ezzi, A. A. A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14089 · Cited by 31
Yao, H., Tong, W., Song, Y., Li, R., Xiang, X., Cheng, W., Zhou, Y., He, Y., Yang, Y., Liu, Y., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03234-0 · Cited by 33
“Excessive synaptic pruning by microglia has been proposed as one of the potential causes for many neurodegenerative diseases [33, 53].”
BackgroundSelf-citationNemeth, D. P., Liu, X., Monet, M. C., Niu, H., Maxey, G., Schrier, M. S., Smirnova, M. I., McGovern, S., Herd, A., DiSabato, D. J., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03287-1 · Cited by 28
“…and down-regulation of mRNA binding was associated with nIL-1R1 expression which could indicate formation of weak synapses tagged for pruning [25, 57] or, as recent studies shows, C1q production can negatively regulate translation through ribonucleoprotein complexes [51] resulting in reduced…”
Inflammatory responses revealed through HIV infection of microglia-containing cerebral organoids
Narasipura, S. D., Zayas, J. P., Ash, M. K., Reyes, A. F., Shull, T. L., Gambut, S., Szczerkowski, J. L. A., McKee, C., Schneider, J. R., Lorenzo-Redondo, R., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03353-2 · Cited by 38
Complement and the hallmarks of cancer
Artero, M. R., Minery, A., Nedelcev, L., Radanova, M. A., & Roumenina, L. T. (2025) · Seminars in Immunology · doi:10.1016/j.smim.2025.101950 · Cited by 37
Han, L., Wei, S., Wang, R., Liu, Y., Zhong, Y., Fu, J., Luo, H., & Bao, M. (2025) · Biomolecules · doi:10.3390/biom15081188 · Cited by 32
“Neuroinflammation may be a prerequisite for the development of hallmark AD features, such as synaptic loss and A β deposition [29–31].”
Lutz, B. M., & Peng, J. (2018) · Proteomes · doi:10.3390/proteomes6040046 · Cited by 27
“Complement C3 is released from microglia and is involved in phagocytosis [55].”
BackgroundAksenova, M. V., Sybrandt, J., Cui, B., Sikirzhytski, V., Ji, H., Odhiambo, D. A., Lucius, M. D., Turner, J. R., Broude, E. V., Peña, E. A., et al. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09885-8 · Cited by 24
Normal ageing of the brain: Histological and biological aspects
Teissier, T., Boulanger, É., & Deramecourt, V. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.03.017 · Cited by 40
A multispecies probiotic accelerates fear extinction and inhibits relapse in mice: Role of microglia
Cui, X., Zhou, S., Xia, G., Chen, J., Jiang, L., Huang, J., & Tong, J. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108613 · Cited by 26
Tang, H., & Harte, M. (2021) · Genes · doi:10.3390/genes12111753 · Cited by 28
Genetic Insights into the Impact of Complement in Alzheimer’s Disease
Torvell, M., Carpanini, S. M., Daskoulidou, N., Byrne, R. A. J., Sims, R., & Morgan, B. P. (2021) · Genes · doi:10.3390/genes12121990 · Cited by 32
“The demonstration that mice deficient in C1q or C3 show reduced synapse loss emphasises the importance of this process [23].”
Aß Pathology and Neuron–Glia Interactions: A Synaptocentric View
Huffels, C. F. M., Middeldorp, J., & Hol, E. M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03699-6 · Cited by 31
“The pro-inflammatory microglia response has been implicated in excessive synaptic pruning in many neurodegenerative diseases, including AD [19, 254].”
BackgroundNiraula, A., Fasnacht, R. D., Ness, K. M., Frey, J. M., Cuschieri, S. A., Dorfman, M. D., & Thaler, J. P. (2022) · Diabetes · doi:10.2337/db21-1072 · Cited by 31
The Breakthroughs and Caveats of Using Human Pluripotent Stem Cells in Modeling Alzheimer’s Disease
Bendtsen, K. M., & Hall, V. J. (2023) · Cells · doi:10.3390/cells12030420 · Cited by 33
Hou, L., Liu, J., Sun, F., Huang, R., Chang, R., Ruan, Z., Wang, Y., Zhao, J., & Wang, Q. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02732-x · Cited by 32
“found that mice with Mac1 deficiency were more resistant to synapse loss and neuronal damage induced by β-amyloid than WT mice [56].”
BackgroundAnimal models of Alzheimer’s disease: preclinical insights and challenges
Xu, Q., Yang, W., Zhong, M., Lin, Z., Gray, N. E., & Xian, Y. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0001 · Cited by 45
Amylin Enhances Amyloid-β Peptide Brain to Blood Efflux Across the Blood-Brain Barrier
Mohamed, L. A., Zhu, H., Mousa, Y. M., Wang, E., Qiu, W. Q., & Kaddoumi, A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160800 · Cited by 28
Microglia-mediated synaptic elimination in neuronal development and disease
Whitelaw, B. S. (2018) · Journal of Neurophysiology · doi:10.1152/jn.00021.2017 · Cited by 27
Convergent molecular defects underpin diverse neurodegenerative diseases
Tofaris, G. K., & Buckley, N. J. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316988 · Cited by 31
Bedoui, Y., Neal, J. W., & Gasque, P. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9793-6 · Cited by 29
Therapeutic effect of Rho kinase inhibitor FSD‑C10 in a mouse model of Alzheimer's disease
Gu, Q., Yu, J., Wu, H., Li, Y., Liu, C.-Y., Feng, L., Zhang, G., Xiao, B., & Ma, C. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6701 · Cited by 27
“It has become clear that cognitive dysfunction more strongly correlates with synapse loss in AD than with counts of plaques, tangles, and neuronal loss (25,26).”
Wu, J., Wu, A., Zhou, X., Khan, I., Zhang, R. L., Lo, H. H., Li, Q., Song, L., Yun, X. Y., Wang, H. M., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105697 · Cited by 29
Medawar, E., Benway, T. A., Liu, W., Hanan, T. A., Haslehurst, P., James, O. T., Yap, K., Muessig, L., Moroni, F., Nahaboo Solim, M. A., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.006 · Cited by 26
“Recently interesting evidence has been presented that Aβ stimulates microglia to phagocytose synapses in a complement dependentmanner at early stages of plaque development in J20 (APPSwe/Ind)mice [31] leading to the hypothesis that microglia are causing early synaptic damage.”
BackgroundAstrocytes regulate neuronal network activity by mediating synapse remodeling
Kim, N., & Chung, W. (2022) · Neuroscience Research · doi:10.1016/j.neures.2022.09.007 · Cited by 31
Guo, L., Yang, X., Zhang, Y., Xu, X., & Li, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1077732 · Cited by 30
Clusterin is a Potential Therapeutic Target in Alzheimer’s Disease
Palihati, N., Tang, Y., Yin, Y., Yu, D., Liu, G., Quan, Z., Ni, J., Yan, Y., & Qing, H. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03801-1 · Cited by 28
“Increased C1q activation activates downstream classical complement pathways and the actions of phagocytic microglia, ultimately leading to synaptic damage [89].”
Sweeney, N., Kim, T. Y., Morrison, C. T., Li, L., Acosta, D. M., Liang, J., Datla, N. V., Fitzgerald, J. A., Huang, H., Liu, X., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02810-1 · Cited by 30
“Given that synaptic dysfunction contributes to cognitive deficits [29, 36, 51, 108], we further analyzed cognitive function and the exploratory and locomotor activity after TBI using Y-maze and the open-field test, respectively.”
MethodCaramello, A., Fancy, N. N., Tournerie, C., Eklund, M., Chau, V. M. N., Adair, E., Papageorgopoulou, M., Willumsen, N., Jackson, J., Hardy, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60328-w · Cited by 44
Xia, H., Feng, Y., Zhu, H., Yang, D., Wang, C., Wang, Z., Zhang, H., Pan, W., Zhao, Y., Initiative, A. D. N., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03432-1 · Cited by 41
“Further longitudinal human trials and animal studies are warranted to validate our fi ndings and elucidate the underlying molecular mechanisms.”
Dayon, L., Wojcik, J., Galindo, A. N., Corthésy, J., Cominetti, O., Oikonomidi, A., Henry, H., Migliavacca, E., Bowman, G. L., & Popp, J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170426 · Cited by 28
Fang, W., Liao, W., Zheng, Y., Huang, X., Weng, X., Fan, S., Chen, X., Zhang, X., Chen, J., Xiao, S., et al. (2019) · Europe PMC (PubMed Central) · Cited by 37
Pharmacological Strategies to Improve Dendritic Spines in Alzheimer’s Disease
Ettcheto, M., Busquets, O., Cano, A. C., Sánchez‐López, E., Manzine, P. R., Espinosa-Jiménez, T., Verdaguer, E., Sureda, F. X., Olloquequi, J., Castro-Torres, R. D., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201106 · Cited by 28
“…this process in AD is orchestrated by soluble A (cid:2) oligomers and it is mediated through CR3 complement-dependent pathway and microglia that engulfs synapses which position microglia as potential cellular mediators of synapse loss independently or before brain plaques formation [84].”
Meier, I. B., Teixeira, C. V. L., Tarnanas, I., Mirza, F., & Rajendran, L. (2021) · Brain Communications · doi:10.1093/braincomms/fcab012 · Cited by 26
“It is equally possible that SARS-CoV-2 does not cross the BBB or gain entry to the CNS, however, through peripheral inflammation as witnessed in the case of HIVassociated neurodegeneration (Hu et al., 2016).”
BackgroundSakakibara, Y., Hirota, Y., Ibaraki, K., Takei, K., Chikamatsu, S., Tsubokawa, Y., Saito, T., Saido, T. C., Sekiya, M., & Iijima, K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210385 · Cited by 27
Microglia in CNS infections: insights from Toxoplasma gondii and other pathogens
Cowan, M. N., Sethi, I., & Harris, T. H. (2022) · Trends in Parasitology · doi:10.1016/j.pt.2021.12.004 · Cited by 28
Maras, P. M., Hebda-Bauer, E. K., Hagenauer, M. H., Hilde, K. L., Blandino, P., Watson, S. J., & Akil, H. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01821-4 · Cited by 26
“…increased expression of C1q (Smith et al., 2019) and CR3 (Streit et al., 1999; Sugama et al., 2007; Graeber, 2010), both known to serve synaptic pruning functions via their roles in the classical complement cascade (Stevens et al., 2007b; Schafer et al., 2012; Shi et al., 2015; Hong et al., 2016).”
BackgroundLü, L., Liu, X., Fu, J., Liang, J., Hou, Y., & Dou, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-10973-8 · Cited by 36
Brain injury environment critically influences the connectivity of transplanted neurons
Grade, S., Thomas, J. M., Zarb, Y., Thorwirth, M., Conzelmann, K., Hauck, S. M., & Götz, M. (2022) · Science Advances · doi:10.1126/sciadv.abg9445 · Cited by 31
Liang, C., Jiang, Y., Zhang, T., Ji, Y., Zhang, Y., Sun, Y., Li, S., Qi, Y., Wāng, Y., Cai, Y., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.159600 · Cited by 29
Self-citationLiu, Y., Chen, Y., Gong, Y., Yang, H., & Liu, J. (2023) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c05512 · Cited by 28
Let’s make microglia great again in neurodegenerative disorders
Guillot‐Sestier, M., & Town, T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1792-x · Cited by 31
“Complement cascade components C1q, C3 and C3 receptor regulate microglial synaptic pruning in AD (Hong et al. 2016).”
Cao, M., Hu, P., Zhang, Y., Yan, Y., Shields, C. B., Zhang, Y., Hu, G., & Xiao, M. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12790 · Cited by 30
Cavanagh, C., & Wong, T. P. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.01.003 · Cited by 29
Hu, J., Yang, Y., Wang, M., Yao, Y., Chang, Y., He, Q., Ma, R., & Li, G. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.02.020 · Cited by 26
Zhou, R., Yang, G., & Shi, Y. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.09.004 · Cited by 26
Alzheimer’s Disease: the Potential of Epigenetic Treatments and Current Clinical Candidates
Coneys, R., & Wood, I. C. (2020) · Neurodegenerative Disease Management · doi:10.2217/nmt-2019-0034 · Cited by 27
CUB and Sushi Multiple Domains 1 (CSMD1) opposes the complement cascade in neural tissuesPreprint
Baum, M. L., Wilton, D. K., Muthukumar, A. K., Fox, R. G., Carey, A. E., Crotty, W., Scott‐Hewitt, N., Bien, E., Sabatini, D. A., Lanser, T. B., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.11.291427 · Cited by 26
“…impairments are seen in several models of brain disease in which enhanced complement activity and microglial dependent synaptic pruning have been implicated, including Alzheimer’s disease, and West Nile virus-induced memory impairment (Hong et al., 2016; Schafer et al., 2016; Vasek et al., 2016).”
BackgroundMethodSelf-citationZelek, W. M., Bevan, R. J., & Morgan, B. P. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.03.017 · Cited by 27
Wan, H., He, M., Cheng, C., Yang, K., Wu, H., Cong, P., Huang, X., Zhang, Q., Shi, Y., Hu, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202403064 · Cited by 46
Reactive microglia partially envelop viable neurons in prion diseases
Makarava, N., Safadi, T., Bocharova, O. V., Mychko, O., Pandit, N. P., Molesworth, K., Baiardi, S., Zhang, L., Parchi, P., & Baskakov, I. V. (2024) · Journal of Clinical Investigation · doi:10.1172/jci181169 · Cited by 31
Modern approaches to investigating non‐neuronal aspects of Alzheimer's disease
Liddelow, S. A. (2019) · The FASEB Journal · doi:10.1096/fj.201802592 · Cited by 27
Bello-Medina, P. C., González-Franco, D. A., Vargas-Rodríguez, I., & Díaz-Cintra, S. Y. (2019) · Neurología · doi:10.1016/j.nrl.2019.06.002 · Cited by 28
Mercurio, D., Oggioni, M., Fumagalli, S., Lynch, N. J., Roscher, S., Minuta, D., Perego, C., Ippati, S., Wallis, R., Schwaeble, W., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01041-1 · Cited by 28
Brennan, G. P., Curran, M. M., Patterson, K. P., Luo, R., & Baram, T. Z. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.615802 · Cited by 27
Tooth Loss Induces Memory Impairment and Gliosis in App Knock-In Mouse Models of Alzheimer’s Disease
Taslima, F., Jung, C., Zhou, C., Abdelhamid, M., Abdullah, M., Goto, T., Saito, T., Saido, T. C., & Michikawa, M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201055 · Cited by 29
Alternative Targets to Fight Alzheimer’s Disease: Focus on Astrocytes
Valenza, M., Facchinetti, R., Menegoni, G., Steardo, L., & Scuderi, C. (2021) · Biomolecules · doi:10.3390/biom11040600 · Cited by 26
Utz, J., Berner, J., Munoz, L. E., Oberstein, T. J., Kornhuber, J., i, M. H., Maler, J. M., & Spitzer, P. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.682115 · Cited by 27
Rupprecht, R., Rupprecht, C., Benedetto, B. D., & Rammes, G. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1961503 · Cited by 27
“2021 Informa UK Limited, trading as Taylor & Francis Group disease or neuropsychiatric disorders such as major depressive disorder (MDD) (Hong et al. 2016; Roman et al. 2020; Rupprecht et al. 2021).”
BackgroundFosL1 Is a Novel Target of Levetiracetam for Suppressing the Microglial Inflammatory Reaction
Niidome, K., Taniguchi, R., Yamazaki, T., Tsuji, M., Itoh, K., & Ishihara, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010962 · Cited by 26
Functional role of brain-engrafted macrophages against brain injuries
Feng, X., Frias, E. S., Paladini, M. S., Chen, D., Boosalis, Z., Becker, M., Gupta, S., Liu, S., Gupta, N. M., & Rosi, S. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02290-0 · Cited by 25
Hisaoka‐Nakashima, K., Ohata, K., Yoshimoto, N., Tokuda, S., Yoshii, N., Nakamura, Y., Wang, D., Liu, K., Wake, H., Yoshida, T., et al. (2022) · Experimental Neurology · doi:10.1016/j.expneurol.2022.114146 · Cited by 30
Interleukin 22 and its association with neurodegenerative disease activity
Chen, W., Wang, J., Yang, H., Sun, Y., Chen, B., Liu, Y., Han, Y., Shan, M., & Zhan, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.958022 · Cited by 33
Cooper, O., Hallett, P. J., & Isacson, O. (2022) · FEBS Journal · doi:10.1111/febs.16638 · Cited by 28
Liu, L., Hu, Y. H., Liu, Y., Shi, D.-W., Liu, C., Da, X., Zhu, S.-H., Zhu, Q., Zhang, J., & Xu, G. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1021129 · Cited by 28
“Synaptic proteins including postsynaptic density protein (PSD)-95 and synaptophysin (SYN), with the reductions of these synaptic markers suggesting synaptic loss, potentially leading to cognitive impairment (Hong et al., 2016).”
BackgroundLuo, X., Fang, Z., Lin, L., Xu, H., Huang, Q., & Zhang, H. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04410-3 · Cited by 29
“It has been demonstrated that the inappropriately activated component system mediates the synaptic loss in mouse models of Alzheimer’s disease [9].”
BackgroundMaurya, S. K., Gupta, S., & Mishra, R. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1072046 · Cited by 29
Liao, X., Chen, M., & Li, Y. (2023) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2023.101064 · Cited by 25
Maleki, A. F., Cisbani, G., Plante, M.-M., Préfontaine, P., Laflamme, N., Gosselin, J., & Rivest, S. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01893-3 · Cited by 26
Hanger, B., Couch, A. C. M., Rajendran, L., Srivastava, D. P., & Vernon, A. C. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00789 · Cited by 25
“Studies in the mouse brain provide evidence for the engulfment of synaptic material in an activity and complement dependent manner, which is exacerbated in mice with pathology associated with neurodegeneration, such as amyloid-b plaque formation (74, 77).”
BackgroundThe cholesteryl ester transfer protein (CETP) raises cholesterol levels in the brain
Oestereich, F., Yousefpour, N., Yang, E., Phénix, J., Nezhad, Z. S., Nitu, A., Cobá, A. V., Ribeiro‐da‐Silva, A., Chaurand, P., & Munter, L. M. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100260 · Cited by 26
“We then further focused on the complement factor C1q given its role in Alzheimer’s disease, inflammation, and cholesterol clearance (25, 39, 40).”
BackgroundInfluentialLuo, L., Chen, J., Wu, Q., Yuan, B., Hu, C., Yang, T., Wei, H., & Li, T. (2023) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2023.104090 · Cited by 25
Li, S.-J., Ma, M., Li, J., Lu, X.-Y., Lu, C., Zhou, S.-F., Zhang, L.-X., Li, M.-Q., Shao, T.-Z., Bai, S., et al. (2023) · Aging and Disease · doi:10.14336/ad.2023.0228 · Cited by 24
Self-citationInflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond
Garmendia, J. V., Sanctis, C. V. D., Das, V., Annadurai, N., Hajdúch, M., & Sanctis, J. B. D. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231017141636 · Cited by 30
“As described earlier, complement is produced by different cells in the CNS and autoantibodies against the abnormal proteins have been detected [309].”
BackgroundNeurotoxic microglial activation via IFNγ-Induced Nrf2 reduction exacerbating alzheimer's disease
Kang, Y. J., Hyeon, S. J., McQuade, A., Lim, J., Baek, S. H., Diep, Y. N., Do, K. V., Jeon, Y., Jo, D., Lee, C. J., et al. (2024) · Advanced Science · doi:10.1002/advs.202304357 · Cited by 27
Mackey-Alfonso, S. E., Butler, M. J., Taylor, A., Williams-Medina, A. R., Muscat, S. M., Fu, H., & Barrientos, R. M. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.07.021 · Cited by 26
“Furthermore, blocking complement protein C1q and the complement (C3) receptor increased the number of functional synapses (Hong, 2016; Shi, 2017; Czirr, 2017).”
BackgroundGe, T.-Q., Guan, P.-P., & Wang, P. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105868 · Cited by 29
Daniilidou, M., Holleman, J., Hagman, G., Kåreholt, I., Aspö, M., Brinkmalm, A., Zetterberg, H., Blennow, K., Solomon, A., Kivipelto, M., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03072-x · Cited by 28
Alemán-Villa, K. M., Armienta-Rojas, D. A., Camberos-Barraza, J., Rábago-Monzón, Á. R., Camacho-Zamora, A., Osuna‐Ramos, J. F., Magaña‐Gómez, J. A., Guadrón‐Llanos, A. M., Calderón-Zamora, L., Norzagaray-Valenzuela, C. D., et al. (2025) · NeuroImmunoModulation · doi:10.1159/000548021 · Cited by 41
“This mechanism, although beneficial during development, becomes detrimental when aberrantly reactivated in the adult brain, contributing to pathological synapse loss in neurodegenerative disorders [49] (Fig.”
Arinuma, Y. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000554 · Cited by 23
Zhao, L., Zhou, C., Shi, H., Liu, J.-W., Shi, J.-W., Kan, B., Li, Z., Yu, J., & Han, J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.228760 · Cited by 26
“As an important marker of synaptic reconstruction, synaptophysin is widely used for labeling axon terminals, reflecting the occurrence and density of synapses (Dan et al., 2008; Brewer et al., 2009; Hong et al., 2016; Pan et al., 2016; Stoyanova et al., 2016).”
BackgroundRen, M., Hu, Z., Chen, Q., Jaffe, A. E., Li, Y., Sadashivaiah, V., Zhu, S., Rajpurohit, N., Shin, J. H., Xia, W., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0530-1 · Cited by 22
Selective neuronal vulnerability in Alzheimer’s disease
Wang, Z.-T., Zhang, C. M., Wang, Y., Dong, Q., Tan, L., & Yu, J. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101114 · Cited by 26
Synaptic Pruning in Alzheimer’s Disease: Role of the Complement System
Brucato, F. H., & Benjamin, D. E. (2020) · Global Journal of Medical Research · doi:10.34257/gjmrfvol20is6pg1 · Cited by 30
Pedersen, H., Jensen, R. K., Jensen, J. M. B., Fox, R. G., Pedersen, D. V., Olesen, H. G., Hansen, A. G., Christiansen, D., Mazarakis, S. M., Lojek, N. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000752 · Cited by 23
Self-citationZhang, Y., Shao, W., Wu, J., Huang, S., Yang, H., Luo, Z., Zheng, F., Wang, Y., Cai, P., Guo, Z., et al. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.111424 · Cited by 24
Zhang, H., Wang, H., Gao, F., Yang, J. Y., Xu, Y., Fu, Y., Cai, M., Zhang, X., Yang, Q., Tong, K., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.06.020 · Cited by 24
Unraveling Human Brain Development and Evolution Using Organoid Models
Fernandes, S., Klein, D., & Marchetto, M. C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.737429 · Cited by 30
Metadata
- Authors
- Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., Lemere, C. A., Selkoe, D. J., & Stevens, B.
- Affiliations
- Boston Children's Hospital (US)
- Brigham and Women's Hospital (US)
- University of California, San Francisco (US)
- Stanford Medicine (US)
- Broad Institute (US)
- Corresponding author
- Beja-Glasser, Victoria F.
- Nfonoyim, Bianca M.
- Stevens, Beth
- ORCID
- Venue
- Science
- Published
- 2016-05-06
- Volume
- 352
- Issue
- 6286
- Pages
- 712-716
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5094372
- OpenAlex
- W2314634699
- Cited by
- 3,343
- References
- 33
- Citations by year
- 2026: 415 · 2025: 391 · 2024: 384 · 2023: 388 · 2022: 324 · 2021: 363 · 2020: 306 · 2019: 260 · 2018: 240 · 2017: 198 · 2016: 69
- FWCI
- 140.04
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Edward R. and Anne G. Lefler Fellowship
- Coins for Alzheimer's Research Trust
- Fidelity Biosciences Research Initiative
- JPB Foundation
- National Institutes of Health (AG000222)
- National Institute of Neurological Disorders and Stroke-NIH (R01NS083845)
- National Institute on Aging-NIH (1RF1AG051496A)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- Alzheimer's disease, synaptic loss, complement system, microglia, C1q, CR3, complement C3, soluble amyloid-beta oligomers, neuroinflammation, synaptic pruning, hippocampal long-term potentiation, phagocytosis, mouse model
- MeSH terms
- Disks Large Homolog 4 Protein, Alzheimer Disease, Animals, Cognition Disorders, Complement Pathway, Classical, Disease Models, Animal, Membrane Proteins, Phagocytosis, Synapses, Up-Regulation, Complement C1q, Macrophage-1 Antigen, Amyloid beta-Peptides, Synaptophysin, Microglia, Long-Term Potentiation, Mice, Knockout, Mice, Guanylate Kinases, CA1 Region, Hippocampal, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.